Abstract: Objective To investigate the changes of serum miR-335 levels in patients with hepatocellular carcinoma （HCC） undergoing transcatheter arterial chemoembolization （TACE）. Methods 60 patients with HCC,50 with chronic hepatitis B （CHB）,50 with hepatitis B liver cirrhosis （LC） and 50 healthy persons were recruited in our hospital between May 2014 and May 2016. All patients with HCC received TACE for average three times and followed-up for 24 months. Serum miR-335 levels were detected by real-time quantitative reverse transcription PCR,and the prognosis of patients with HCC by serum miR-335 levels was predicted by the area under the curve of receiver-operating characteristic. Results Serum miR-335 level in patients with HCC was（1.18±1.35）,much lower than （1.91±2.11） in patients with CHB,or （2.01±0.75） in patients with LC,and also significantly lower than【（2.07±1.25）,P=0.001】 in healthy persons;serum miR-335 level in 22 HCC patients with portal vain tumor thrombus was significantly lower than in 38 patients without（t=4.586,P<0.001）,serum miR-335 level in 13 dead patients was much lower than in 47 survivals（t=3.324,P<0.001）,while those in patients with different gender,age,tumor sise,TNM stage,serum AFP levels and with or without lymph node metastasis were not significantly different （all P>0.05）;the sensitivity was 83.0% and the specificity was 100.0% when serum miR-335 level being 0.820 was set for the cut-off-value for predicting the two-year patients’ death. Conclusion Serum miR-335 levels in patients with HCC decrease,and the lower the serum miR-335 levels,the poorer the prognosis,which warrants further investigation.

Key words: Hepatocellular carcinoma, miR-335, Transcatheter arterial chemoembolization, Prognosis